Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects (PO206)
This study has been completed.
Sponsor:
Adamas Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Adamas Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00979251
First received: September 16, 2009
Last updated: June 8, 2012
Last verified: June 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | August 2011 |
| Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |